MRNA-1283: Difference between revisions
Content deleted Content added
Misc citation tidying. | Use this bot. Report bugs. | #UCB_CommandLine 1198/1853 |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 46: | Line 46: | ||
'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web||title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web||title=A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |url=https://clinicaltrials.gov/ct2/show/NCT05137236 |website=[[ClinicalTrials.gov]] |date=30 November 2021 |id=NCT05137236 |access-date=30 November 2021 }}</ref> |
'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web||title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web||title=A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |url=https://clinicaltrials.gov/ct2/show/NCT05137236 |website=[[ClinicalTrials.gov]] |date=30 November 2021 |id=NCT05137236 |access-date=30 November 2021 }}</ref> |
||
Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with [[vaccine storage]] in a standard refrigerator, rather than low temperature freezers.<ref>{{cite web |title=Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine | url=https://news.modernatx.com/news/news-details/2024/Moderna-Achieves-Positive-Interim-Results-from-Phase-3-Trial-of-Next-Generation-COVID-19-Vaccine/default.aspx|website=news.modernatx.com|access-date=30 May 2024}}</ref> Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.<ref>{{cite web |title=Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine | url=https://news.modernatx.com/news/news-details/2024/Moderna-Achieves-Positive-Interim-Results-from-Phase-3-Trial-of-Next-Generation-COVID-19-Vaccine/default.aspx|website=news.modernatx.com|access-date=30 May 2024}}</ref> |
|||
An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 °C). <ref name=":0">{{Cite web |title=CTG Labs - NCBI |url=https://clinicaltrials.gov/study/NCT05815498 |access-date=2023-08-01 |website=clinicaltrials.gov}}</ref> |
|||
== Clinical Trial == |
== Clinical Trial == |
||
In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.<ref name="pmid37074202">{{cite journal | vauthors = Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R | title = Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults | journal = Human Vaccines & Immunotherapeutics | volume = 19 | issue = 1 | pages = 2190690 | date = December 2023 | pmid = 37074202 | pmc = 10128428 | doi = 10.1080/21645515.2023.2190690 }}</ref> As of |
In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.<ref name="pmid37074202">{{cite journal | vauthors = Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R | title = Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults | journal = Human Vaccines & Immunotherapeutics | volume = 19 | issue = 1 | pages = 2190690 | date = December 2023 | pmid = 37074202 | pmc = 10128428 | doi = 10.1080/21645515.2023.2190690 }}</ref> As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.<ref>{{cite web |title=A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE) |url=https://www.clinicaltrials.gov/study/NCT05815498 |website=ClinicalTrials.org |access-date=30 May 2024}}</ref> Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.<ref>{{cite web |title=Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine | url=https://news.modernatx.com/news/news-details/2024/Moderna-Achieves-Positive-Interim-Results-from-Phase-3-Trial-of-Next-Generation-COVID-19-Vaccine/default.aspx|website=news.modernatx.com|access-date=30 May 2024}}</ref> |
||
An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature. <ref name=":0" /> |
|||
== References == |
== References == |
||
Latest revision as of 20:39, 30 May 2024
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Trade names | Spikevax[1] |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]
Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with vaccine storage in a standard refrigerator, rather than low temperature freezers.[4] Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.[5]
Clinical Trial
[edit]In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[6] As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.[7] Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.[8]
References
[edit]- ^ "Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day". Bloomberg. 9 September 2021. Retrieved 29 April 2022.
- ^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
- ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
- ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
- ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
- ^ Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R (December 2023). "Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults". Human Vaccines & Immunotherapeutics. 19 (1): 2190690. doi:10.1080/21645515.2023.2190690. PMC 10128428. PMID 37074202.
- ^ "A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)". ClinicalTrials.org. Retrieved 30 May 2024.
- ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
Scholia has a profile for mRNA-1283 (Q110263526).
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |